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Experiment Hypothesis 
    The combined effect of anti-resorptive 
drugs plus in-flight exercise regimen will 
have a measurable effect in preventing 
space flight induced bone mass and 
strength loss and reducing renal stone 
risk. 
 
 
 
Experiment Status  
• To date 7 subjects are enrolled -- 70-mg tablet 
of alendronate once a week before and during 
flight, starting 17 days before launch  
• 5 crewmembers have completed ISS long 
duration missions and will be reported here.  
•  2 additional crewmembers are scheduled to 
complete the flight portion of the protocol this 
year 
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*p value statistically significant when Holm correction for multiple comparisons is applied  
p = 0.034 p = 0.055 p < 0.000 * 
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Urinary Calcium During and After Space Flight  (Mean ± SE) 
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Preliminary Results 
Objectives of the Current Study 
Extension 
• Current controls are ISS astronauts who 
exercised using IRED. 
• All subjects in the current study have used 
ARED, capable of higher loading and 
more efficient usage.  
• New control group will help clarify the 
impact of ARED alone. 
 
 
protocol 
• 10 long duration ISS crew-male or female 
• Exercise with ARED protocol 
• Exclude subjects participating in Sprint 
protocol-Sprint controls can be enrolled 
• Exclude subjects taking drugs targeting 
bone loss 
 
 
 
 
Experiment Measurements 
QCT: L-45 to L-30 , R+5, R+360 
 Imaging scan of the hip for measurement of volumetric bone density,  
 strength modeling  
 Performed at local hospital 
 Scan takes < 15 minutes; 1 hour allotted for travel time + scanning 
 Can data share with Sprint study if subject is a Sprint control 
 
DXA: L-60 to L-30, R+5, R+360 
 Imaging scan of the whole body, hip, spine, heel and wrist for measurement  
 of areal bone mineral density 
 Performed at JSC 
 Scans take ~ 1 hour 
 Will data share with existing DXA Medical Requirement 
 
pQCT: L-60 to L-30, R+5, R+360 
 Imaging scan of the lower leg (tibia) for measurement of volumetric bone density 
 Performed at JSC 
 Scans take ~50 minutes 
 
 
Experiment Measurements 
Urine Collections: 
 L-45 , Early In-Flight, Mid In-Flight, Late In-Flight, R+0, R+30, R+360 
 Levels of various markers of bone metabolism will be measured 
 24-hour void-by-void 
 Can data share with Medical Requirements or other studies (e.g., Nutrition SMO) 
Blood Draws: 
 L-45, R+0, R+30, R+360 
 Levels of various markers of bone metabolism will be measured 
 Standard blood draw 
 Can data share with Medical Requirements or other studies (e.g., Nutrition SMO) 
 Blood draw takes < 10 minutes 
Abdominal Ultrasound: 
 L-30 to 180, R+30 
 Imaging of bladder, ureters and kidneys for presence of renal stones 
 Performed at local imaging facility 
 Ultrasound takes ~ 1.5 hour, including travel time 
Calcium and Vitamin D supplements: 
 Vitamin D: 800 IU daily from L-45 to launch; Ca: 1000 mg daily from L-17 to launch 
  
  
Test Constraints 
QCT Remove all metal (i.e., jewelry) or clothes containing metal 
No radioisotopes or radio opaque contrast agents for one 
week prior to test. 
DXA Remove all metal (i.e., jewelry) or clothes containing metal 
No radioisotopes or radio opaque contrast agents for one 
week prior to test. 
pQCT Remove all metal (i.e., jewelry) or clothes containing metal 
No radioisotopes or radio opaque contrast agents for one 
week prior to test. 
Urine collections 24-hr. urine collection starts with first void of the day and 
concludes with first void of the following day 
Blood draws Overnight fast 
Ultrasound Overnight fast 
Arrive at imaging center with full bladder (drink 32 oz. of 
water before arrival) 
Test Constraints 
Preflight Inflight Postflight 
QCT:  60 min * QCT:  120 min * 
DXA:  60 min * DXA:  120 min * 
pQCT:  50 min  pQCT:  100 min  
Blood draw:  10 min *  Blood draw:  30 min *  
Urine collection: 30 min * Urine collections:  510 min 
* 
Urine collection: 90 min * 
Abdominal ultrasound: 90 
min 
Abdominal ultrasound: 90 
min 
Ca and Vitamin D: 30 
sec/day, 22.5 min total  
Total Time:  322.5 min Total Time:  510 min  Total Time: 550 min  
Summary 
* Potential for data sharing with Med Requirements or other studies 
